Government will decide on vaccination of children, adolescents on 'scientific rationale', supply situation: Covid Task Force Chief
Zydus Cadila's indigenously developed needle-free COVID-19 vaccine ZyCoV-D is set to become the first vaccine that will be available in India for those in the age group of 12-18 years.
The head of the Russian state-controlled fund that invested in the vaccine insisted Wednesday the supply problems have been resolved.
The clarification comes after Russia's Health Minister Mikhail Murashko in recent days reportedly said that administrative issues were among the main holdups in WHO's decision-making process.
Of every 1000 people who have taken shots, less than 1 received Sputnik V, despite its soft launch in India in May through its local partner Dr Reddy's.
Sputnik V is currently manufactured in India and being sold by Dr Reddy's Laboratories under Emergency Use Authorisation route.
This is the first batch of the second component produced and supplied by the company in India, the drug firm and the Russian Direct Investment Fund (RDIF) said in a joint statement.
There is no need to check the antibody levels post-taking the vaccine as some vaccines evoke T-cell immunity (long-term memory of the immune response), says Dr. Subrata Das.
The Deputy Director of Health Services Dr S Senthilkumar said that 10 private hospitals in the district are authorised to administer Covid vaccines. Of them, only two hospitals offer Sputnik V.
Speaking at the launch of the vaccine, Dhami said by December this year, the state government will achieve its target of 100 per cent vaccination.
Production in India is expected to come fully onstream in September and RDIF expects India to become a major production hub for the Sputnik V vaccine.
Both shots use a similar technology, employing a harmless virus to deliver genetic material from the spike protein of COVID-19 into the body.
Manipal Hospitals, Vijayawada, started administering Sputnik V vaccine as part of its COVID-19 vaccination drive.
The high antibody levels after a single Sputnik V dose in naive participants suggest a benefit of delaying second dose administration to increase the number of people vaccinated.
'The first batch of Sputnik vaccine is expected to be produced at SII's facilities in September,' RDIF said in a statement.
The parties intend to produce over 300 million doses of the vaccine in India per year, RDIF said in a statement.